Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + tenofovir disoproxil + raltegravir
- Development stage
- Unknown
- Lead developer
- University of Alberta
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine + tenofovir disoproxil + raltegravir is a combination antiretroviral therapy (cART) regimen being investigated by the University of Alberta for the treatment of primary biliary cholangitis (PBC). This regimen repurposes established HIV medications—specifically two reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil) and one integrase inhibitor (raltegravir)—to target a suspected human betaretrovirus (HBRV) infection hypothesized to drive PBC pathogenesis. The therapy is primarily evaluated in patients who have shown an inadequate response to standard-of-care ursodeoxycholic acid (UDCA). By inhibiting viral replication and integration, the combination aims to reduce liver inflammation and improve biochemical markers of cholestasis in patients with refractory PBC.
- Brand names
- TruvadaIsentress
- Other names
- cART for PBCCombination Antiretroviral Therapy for Primary Biliary Cholangitis
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseIntegrase allosteric pocket (HIV)
Beyond the preview
Go deeper on emtricitabine + tenofovir disoproxil + raltegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + tenofovir disoproxil + raltegravir.